University of Washington is about to start a clinical trial for patients with Streamlined Treatment of Pulmonary Exacerbations in Pediatrics

Photo by Piron Guillaume

The company University of Washington, the Collaborative Health Studies Coordinating Center is commencing recruitment for the clinical trial of the Streamlined Treatment of Pulmonary Exacerbations in Pediatrics.

The condition is Cystic Fibrosis.

A new clinical trial is recruiting patients in the following locations: United States.

The trial officially began on the November 1, 2020 and is planned to complete on June 30, 2023.

STOP PEDS is a pilot study of children with CF ages 6-18 across 10 sites in North America. The primary goal is to assess the acceptability and feasibility of a multicenter randomized trial comparing immediate antibiotics versus tailored therapy for pulmonary exacerbation (PEx) treatment in this population.

Enrollment Inclusion Criteria: 1. Age 6 to <19 years 2. Documentation of a CF diagnosis as evidenced by one or more clinical features consistent with the CF phenotype and one or more of the criteria. 3. Able to perform acceptable and reproducible spirometry 4. FEV1 ≥ 50% predicted at enrollment based on the Global lung Initiative (GLI) reference equations 5. At least 1 course of oral antibiotics for respiratory symptoms in the 12 months prior to enrollment.

Cystic Fibrosis Foundation is the collaborator in this clinical trial.

The link to the complete study profile: https://ichgcp.net/clinical-trials-registry/NCT04608019.